Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E7MA
|
|||
| Former ID |
DIB012683
|
|||
| Drug Name |
ATG002
|
|||
| Indication | Diabetic foot ulcer [ICD-11: BD54; ICD-9: 707] | Phase 1/2 | [1] | |
| Company |
CoMentis
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nicotinic acetylcholine receptor (nAChR) | Target Info | Agonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Highly sodium permeable acetylcholine nicotinic receptors | |||
| Highly calcium permeable postsynaptic nicotinic acetylcholine receptors | ||||
| WikiPathways | Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00316537) Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers. U.S. National Institutes of Health. | |||
| REF 2 | Athenagen Advances Angiogenesis Drug to Clinical Testing. Athenagen. JUNE 21, 2006. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.